Jason Leverone
Equibles does not estimate personal net worth.
Get an email with a short summary when OnKure Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get OKUR alertsAbout Jason Leverone
Jason Leverone is recorded as CFO at OnKure Therapeutics, Inc. (OKUR). The newest filing on record that lists Jason Leverone as CFO at OnKure Therapeutics, Inc. (OKUR) is dated April 21, 2026. Earlier roles on record: CFO at Viridian Therapeutics, Inc.\DE (VRDN) until May 14, 2021. OnKure Therapeutics, Inc. reported in an 8-K filed October 8, 2024 that Jason Leverone was appointed Chief Financial Officer (Principal Financial and Accounting Officer), effective October 4, 2024. OnKure Therapeutics, Inc. reported in an 8-K filed May 13, 2024 that Jason Leverone was appointed Chief Financial Officer. The proxy statement of OnKure Therapeutics, Inc. reports total compensation of $896,167 for Jason Leverone in fiscal 2025, including a base salary of $444,000. Disclosed compensation is on record for 6 fiscal years. Jason Leverone has spoken on 3 earnings calls across 1 company, most recently for Viridian Therapeutics, Inc.\DE on March 25, 2021. OnKure Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Jason Leverone spoke on are classified in the Healthcare sector. Other leadership on record at OnKure Therapeutics, Inc. includes Nicholas A. Saccomano (CEO and Board Member), Nicholas A. Saccomano, Ph.D. (CEO), Nicholas Saccomano (CEO and Board Member) and 7 others.
“On October 4, 2024, the following individuals were appointed to serve as executive officers of the Combined Company:”
“Following the closing of the Proposed Transactions, Dr. Saccomano and Mr. Leverone will be named the President and Chief Executive Officer and Chief Financial Officer, respectively, of Reneo.”
Jason Leverone on recent calls
“We entered 2021 in a strong financial position. And this year, we look to advance multiple programs in thyroid eye disease while expanding our discovery pipeline.”
“In today's press release, we reported our second quarter 2020 financial results. We ended the quarter with $30.6 million in cash and cash equivalents. This compared to $26.8 million of cash, cash equivalents and short-term investments at the end of last year.”
“In today's press release, we reported our first quarter 2020 financial results. We ended the quarter with $36.1 million in cash and cash equivalents compared to $26.8 million of cash, cash equivalents and short-term investments at the end of 2019.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 21, 2026
-
Start not stated–2021-05-14
Company network
Leadership on record at OnKure Therapeutics, Inc.
- Nicholas A. Saccomano CEO, Board Member
- Nicholas A. Saccomano, Ph.D. CEO
- Nicholas Saccomano CEO, Board Member
- Andrew Phillips Chairman, Board Member
- Jennifer P. Lam CFO
- Michael P. Cruse COO
- Andrew Philips, Ph.D. Board Member
- Continuing Directors Board Member
- Dr. Liam Ratcliffe Board Member
- Edward T. Mathers Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | OnKure Therapeutics, Inc. (OKUR) | C.P.A. Chief Financial Officer | $444,000 | $896,167 |
| 2024 | OnKure Therapeutics, Inc. (OKUR) | C.P.A. Chief Financial Officer | $382,958 | $2,678,570 |
| 2023 | OnKure Therapeutics, Inc. (OKUR) | C.P.A. Chief Financial Officer | $346,500 | $791,947 |
| 2020 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial Officer, Treasurer, and Secretary | $365,650 | $483,020 |
| 2019 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial Officer, Treasurer, and Secretary | $355,000 | $537,807 |
| 2018 | Viridian Therapeutics, Inc.\DE (VRDN) | Chief Financial Officer | $340,000 | $824,667 |